Skip to main navigation
Skip to search
Skip to main content
University of Copenhagen Research Portal Home
Help & FAQ
Dansk
English
Home
Profiles
Research output
Research units
Press/Media
Activities
Prizes
???studenttheses???
Datasets
Search by expertise, name or affiliation
Comparative effectiveness and safety of apixaban, dabigatran, and rivaroxaban in patients with non-valvular atrial fibrillation
Niklas W. Andersson, Henrik Svanstrom, Marie Lund, Bjorn Pasternak,
Mads Melbye
Department of Clinical Medicine
13
Citations (Scopus)
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Comparative effectiveness and safety of apixaban, dabigatran, and rivaroxaban in patients with non-valvular atrial fibrillation'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Apixaban
100%
Clinical Practice
11%
Comparative Effectiveness
100%
Comparative Safety
100%
Confidence Interval
66%
Dabigatran
100%
Denmark
11%
Direct Oral Anticoagulants
33%
Effectiveness Outcomes
11%
Hazard Ratio
33%
Historical Cohort Study
11%
Major Bleeding
33%
Matched Comparison
22%
Nationwide Registers
11%
New User
11%
Non-valvular Atrial Fibrillation
100%
Once-daily
11%
Population-based
11%
Propensity Matching
22%
Propensity Score
11%
Rivaroxaban
100%
Routine Clinical Practice
11%
Safety Outcomes
11%
Stroke Risk
22%
Systemic Embolism
33%
Twice Daily
22%
Pharmacology, Toxicology and Pharmaceutical Science
Apixaban
100%
Atrial Fibrillation
100%
Bleeding
33%
Cerebrovascular Accident
33%
Cohort Study
11%
Dabigatran
100%
Direct Oral Anticoagulant
33%
Rivaroxaban
100%